Your patient with MS is prescribed interferon beta (Betaseron). What is a priority for teaching at this time?

A. Interferon beta (Betaseron) can cause hepatotoxicity, which is monitored through periodic liver function tests. Patients are typically taught to report jaundice, dark urine, or abdominal pain, but this is not the most immediate concern when starting therapy. Teaching about hepatotoxicity supplements injection training but does not replace hands-on instruction in medication administration. B. Teaching proper self-injection technique is the priority when a patient begins interferon beta therapy. Betaseron is a subcutaneous injection often administered at home, so the patient or caregiver must know how to: rotate injection sites, use aseptic technique, handle pre-filled syringes, and properly dispose of sharps. Correct technique reduces the risk of injection-site reactions, infection, and medication waste, and ensures the patient receives the full therapeutic dose consistently. Initial teaching should focus on demonstration, return demonstration, and review of step-by-step instructions before the patient attempts independent injections. C. Interferon beta does not cause a blue tint to urine or skin. This is a misconception and not part of standard patient teaching. Providing incorrect information could cause confusion or unnecessary anxiety. D. Myelosuppression is a potential long-term adverse effect of interferon beta, usually monitored through complete blood counts. Patients should be instructed to report signs of infection, unusual bruising, or fatigue, but initial teaching should focus on safe self-administration, as this is the most immediate concern for treatment adherence and safety.